COVAX also confirmed that it will exercise an existing agreement with the Serum Institute of India (SII) - to receive its first 100 million doses of the AstraZeneca/Oxford University-developed vaccine manufactured by SII. It anticipates that, via an existing agreement with AstraZeneca, 100 million doses of the vaccine will be available for delivery in the first quarter of the year, the release said.
"Today marks another milestone for COVAX: pending regulatory approval for the AstraZeneca/Oxford candidate and pending the successful conclusion of the supply agreement for the Pfizer-BioNTech vaccine, we anticipate being able to begin deliveries of life-saving COVID-19 vaccines by the end of February," said Dr Seth Berkley, CEO of Gavi, the Vaccine Alliance, which leads COVAX procurement and delivery.
"This is not just significant for COVAX, it is a major step forward for equitable access to vaccines, and an essential part of the global effort to beat this pandemic. We will only be safe anywhere if we are safe everywhere," Berkley added.
"The urgent and equitable rollout of vaccines is not just a moral imperative, it's also a health security, strategic and economic imperative," said Dr Tedros Adhanom Ghebreyesus, Director-General of the World Health Organization.
Tedros further stated, "This agreement with Pfizer will help to enable COVAX to save lives, stabilize health systems and drive the global economic recovery."
"These purchase agreements open the door for these lifesaving vaccines to become available to people in the most vulnerable countries," said UNICEF Executive Director Henrietta Fore.
"But at the same time we are securing vaccines we must also ensure that countries are ready to receive them, deploy them, and build trust in them," Fore said further.
The COVAX Facility intends to provide all 190 participating economies with an indicative allocation of doses by the end of this month, the release said.
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.